Immutep (IMMP) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep Limited has announced promising results from its Phase II trial of eftilagimod alpha, combined with pembrolizumab and radiotherapy, for treating soft tissue sarcoma. The combination therapy showed a significant increase in tumor hyalinization, a key predictor of overall survival, compared to standard treatments. These results signal a potential breakthrough for patients with this aggressive cancer type.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.